{"id":3683,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amisulpride-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amisulpride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amisulpride-txt\/","title":{"rendered":"Amisulpride.txt"},"content":{"rendered":"

Amisulpride<\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of acute and chronic
\nschizophrenia
\n

DOSE IN NORMAL RENAL FUNCTION <\/H3>
\n50\u20131200 mg daily (in divided doses if
\n>300 mg); varies according to indication
\n

PHARMACOKINETICS <\/H3>
\n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n369.5\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n16\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n50\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n5.8\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n12\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n30\u201360 Reduce dose by 50%
    \n10\u201330 Use a third of the dose.
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nUse with caution. Start with
    \nminimum dose and increase
    \naccording to patient\u2019s response
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in
    \nGFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nPoorly dialysed. Dose as in
    \nGFR <10 mL\/min
    \n
  • HDF\/high flux &nbsp :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nPoorly dialysed. Dose as in
    \nGFR=10\u201330 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Alcohol: may enhance CNS effects of\n

    alcohol<\/p>\n

  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions\n

    with tramadol; enhanced hypotensive and
    \nsedative effects with opioids<\/p>\n

  • Antiarrhythmics: increased risk of\n

    ventricular arrhythmias with antiarrhythmics that prolong the QT interval;
    \navoid concomitant use with amiodarone,
    \ndisopyramide and procainamide (risk of
    \nventricular arrhythmias)<\/p>\n

  • Antibacterials: avoid concomitant use with\n

    parenteral erythromycin (increased risk of
    \nventricular arrhythmias)<\/p>\n

  • Antidepressants: increased level of\n

    tricyclics<\/p>\n

  • Antiepileptics: antagonises anticonvulsant\n

    effect<\/p>\n

  • Antihypertensives: increased risk of\n

    hypotension<\/p>\n

  • Antimalarials: avoid concomitant use with\n

    artemether\/lumefantrine
    \nAntipsychotics: increased risk of <\/p>\n

    ventricular arrhythmias with sertindole \u2013
    \navoid concomitant use<\/p>\n

  • Antivirals: concentration possibly\n

    increased by ritonavir
    \nAnxiolytics & hypnotics: increased <\/p>\n

    sedative effects<\/p>\n

  • Atomoxetine: increased risk of ventricular\n

    arrhythmias<\/p>\n

  • Beta-blockers: increased risk of ventricular\n

    arrhythmias with sotalol
    \nDiuretics: increased risk of ventricular <\/p>\n

    arrhythmias due to hypokalaemia<\/p>\n

  • Pentamidine: increased risk of ventricular\n

    arrhythmias \u2013 avoid<\/p>\n

  • Sibutramine: increased risk of CNS\n

    toxicity \u2013 avoid concomitant use
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4>
    \nElimination half-life is unchanged in <\/p>\n

    patients with renal insufficiency, while
    \nsystemic clearance is reduced by a factor
    \nof 2.5\u20133. The area under the curve of
    \namisulpride in mild renal failure is
    \nincreased 2-fold, and almost 10-fold in
    \nmoderate renal failure. Experience is
    \nlimited and there is no data with doses
    \n>50 mg<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amisulpride CLINICAL USE Treatment of acute and chronic schizophrenia DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3683","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3683"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3683\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}